Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

John Mascarenhas, MD, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Ruben Mesa, MD, Rami S. Komrokji, MD, Steffen Koschmieder, MD, Alessandro M. Vannucchi, MD, Tymara Berry, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Libo Sun, PhD, Fei Huang, PhD, Ying Wan, PhD, Faye Feller, MD, Aleksandra Rizo, MD PhD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-138915

Published: 2020

Journal Articles

Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-139229

Published: 2020

Journal Articles

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN)

Blood (2018) 132 (Supplement 1): 4292.

https://doi.org/10.1182/blood-2018-99-112377

Published: 2018

Journal Articles

Implication of Hypoxia-Inducible Factor-1 (HIF-1) As a New Therapeutic Target in JAK2 V617F Positive Myeloproliferative Neoplasms (MPN)

Julian Baumeister, MSc, Nicolas Chatain, PhD, Annika Hubrich, Caroline Küstermann, M.Sc., Stephanie Sontag, PhD, Kristin Seré, PhD, Martin Zenke, PhD, Tim H Brümmendorf, MD, Kamil Kranc, MD, Steffen Koschmieder, MD, Deniz Gezer, MD

Blood (2018) 132 (Supplement 1): 4318.

https://doi.org/10.1182/blood-2018-99-113332

Published: 2018

Journal Articles

Eosinophil Differentiation and Viability in Hypereosinophilia Is Impaired By Genetic and Pharmacologic Targeting of LCP1 and PKC Beta

Guangxin Ma, Deniz Gezer, MD, Oliver Herrmann, Msc, Andreas Reiter, MD, Mohamad Jawhar, Mirle Schemionek, Tim H. Brümmendorf, MD, Steffen Koschmieder, MD, Nicolas Chatain, PhD

Blood (2018) 132 (Supplement 1): 4320.

https://doi.org/10.1182/blood-2018-99-114646

Published: 2018

Journal Articles

The Impact of the Mutational Landscape upon the Molecular Responses to Interferon-Alfa2 in Calr-Mutated MPN Patients

Vibe Skov, PhD, Lasse Kjær, PhD, Mads Thomassen, PhD, Steffen Koschmieder, MD, Julia Czech, Nicolas Chatain, PhD, Niels Pallisgaard, Sabrina Cordua, MD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4327.

https://doi.org/10.1182/blood-2018-99-119158

Published: 2018

Journal Articles

Comparison of Fluorescence in Situ Hybridization and Flow Cytometry (Flow-FISH) with Monochrome Multiplex Quantitative Polymerase Chain Reaction (MM-qPCR) for Telomere Length Screening in Adult Patients with Suspected Cryptic Dyskeratosis Congenita (DKC)

Monica Sofia Ventura Ferreira, PhD, Natalia Estrada, Martin Kirschner, MD, Blanca Xicoy, Anne-Sophie Bouillon, MD, Stefan Wilop, MD, Steffen Koschmieder, MD, Jens P. Panse, MD, Tim H. Brümmendorf, MD, Fabian Beier, MD

Blood (2018) 132 (Supplement 1): 3861.

https://doi.org/10.1182/blood-2018-99-117330

Published: 2018

Journal Articles

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Torsten Kessler, MD, Steffen Koschmieder, MD, Christoph Schliemann, MD, Martina Crysandt, Jan-Henrik Mikesch, MD, Matthias Stelljes, MD, Linus Angenendt, Georg Lenz, Anna Kirsch, Kerstin Vehring, Hartmann Wolfgang, Eva Wardelmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, MD, Carsten Mueller-Tidow, Wolfgang E. Berdel, MD

Blood (2018) 132 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2018-99-118095

Published: 2018

Journal Articles

Hematopoietic Stem and Progenitor Cell Proliferation and Differentiation Requires the Trithorax Protein Ash2l In Vivo

Nicolas Chatain, PhD, Juliane Lüscher-Firzlaff, Chao-Chung Kuo, Agnieszka Bochyńska, Andrea Ullius, Bernd Denecke, Ivan Costa, Steffen Koschmieder, MD, Bernhard Lüscher

Blood (2018) 132 (Supplement 1): 2566.

https://doi.org/10.1182/blood-2018-99-115950

Published: 2018

Journal Articles

Androgen Derivatives Improve Blood Counts and Elongate Telomere Length in Patients with Dyskeratosis Congenita

Martin Kirschner, MD, Monica Sofia Ventura Ferreira, PhD, Anne-Sophie Bouillon, MD, Marcin W. Wlodarski, MD PhD, Michaela Schwarz, MD, Stefan Balabanov, MD PhD, Stefan Wilop, MD, Steffen Koschmieder, MD, Jens P. Panse, MD, Tim H. Brümmendorf, MD, Fabian Beier, MD

Blood (2018) 132 (Supplement 1): 2585.

https://doi.org/10.1182/blood-2018-99-118197

Published: 2018

Journal Articles

Characterization of Hematopoietic Differentiation Profiles of MPN Patient-Derived Inducible Pluripotent Stem Cells Harboring Homozygous Vs Heterozygous Calreticulin Mutations

Lijuan Han, MD, Marcelo A. Szymanski Toledo, PhD, Alexandre Theocharides, MD, Angela Maurer, M.Sc, Tim H. Brümmendorf, MD, Martin Zenke, PhD, Nicolas Chatain, PhD, Steffen Koschmieder, MD

Blood (2018) 132 (Supplement 1): 3065.

https://doi.org/10.1182/blood-2018-99-113372

Published: 2018

Journal Articles

Elucidation of Additional Mutations By Next-Generation Sequencing Is of Clinical Significance in Patients with Rare MPNs and MDS/MPN Overlap Syndromes

Martin MJ Kirschner, MD, Mirle Schemionek, PhD, Matthias Begemann, PhD, Susanne Isfort, MD, Kristina Feldberg, Tim H. Brümmendorf, MD, Steffen Koschmieder, MD

Blood (2016) 128 (22): 4260.

https://doi.org/10.1182/blood.V128.22.4260.4260

Published: 2016

Journal Articles

Dasatinib Exerts Differential Effects on Normal and BCR-ABL Positive Hematopoietic Cells in a Transgenic Mouse Model of Chronic Phase-CML

Claudia Schubert, Msc, Nicolas Chatain, PhD, Till Braunschweig, MD, Mirle Schemionek, PhD, Kristina Feldberg, Melanie Hoffmann, Tim H. Brümmendorf, MD, Satu Mustjoki, MD PhD, Olli Dufva, Steffen Koschmieder, MD

Blood (2016) 128 (22): 1885.

https://doi.org/10.1182/blood.V128.22.1885.1885

Published: 2016

Journal Articles

Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110)

Blood (2016) 128 (22): 1939.

https://doi.org/10.1182/blood.V128.22.1939.1939

Published: 2016

Journal Articles

The Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Quality of Life and Productivity: Results from the International MPN Landmark Survey

Claire N. Harrison, DM, FRCP, FRCPath, Steffen Koschmieder, MD, Lynda Foltz, MD FRCP, Paola Guglielmelli, MD, Tina Flindt, AAS, Michael Koehler, Dipl.-Psych., Dr. rer. MDc., Jonathan Mathias, BSc, Norio Komatsu, MD PhD, Robert N. Boothroyd, PharmD, Amber Spierer, MPH, Julian Perez Ronco, MD, Gavin Taylor-Stokes, MBA, John Waller, PhD, Ruben A. Mesa, MD

Blood (2016) 128 (22): 4267.

https://doi.org/10.1182/blood.V128.22.4267.4267

Published: 2016

Journal Articles

Classic Cardiovascular Risk Factors and Certain Comorbidities May Contribute to the Risk of Thrombembolic and Bleeding Events in Patients with Classical Myeloproliferative Neoplasms

Susanne Isfort, MD, Andrea Kaifie, MD, Karla Schmitt, MD, Edgar Jost, MD, Tim H. Bruemmendorf, MD, Steffen Koschmieder, MD

Blood (2015) 126 (23): 5195.

https://doi.org/10.1182/blood.V126.23.5195.5195

Published: 2015

Journal Articles

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Vikas Gupta, MD FRCP, FRCPath, Claire N. Harrison, Hans Hasselbalch, MD, Lisa Pieri, MD PhD, Steffen Koschmieder, MD, Francisco Cervantes, Weichao Bao, PhD, Stacey Kalambakas, MD, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Florian H. Heidel, MD

Blood (2015) 126 (23): 825.

https://doi.org/10.1182/blood.V126.23.825.825

Published: 2015

Journal Articles

A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis

Frank Stegelmann, MD, Markus Bangerter, MD, Florian H Heidel, MD, Martin Griesshammer, MD, Holger Hebart, MD, Andreas Hochhaus, MD, Steffen Koschmieder, MD, Robert Möhle, MD, Andreas Reiter, MD, Christof Scheid, MD PhD, Rebecca Kirschbaum, Regina Reim, Ulrike Sutter, Katrin Vetter, Hartmut Döhner, MD, Richard F. Schlenk, MD, Konstanze Döhner, MD

Blood (2015) 126 (23): 826.

https://doi.org/10.1182/blood.V126.23.826.826

Published: 2015

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia

Blood (2015) 126 (23): 1569.

https://doi.org/10.1182/blood.V126.23.1569.1569

Published: 2015

NARROW

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN)

Implication of Hypoxia-Inducible Factor-1 (HIF-1) As a New Therapeutic Target in JAK2 V617F Positive Myeloproliferative Neoplasms (MPN)

Eosinophil Differentiation and Viability in Hypereosinophilia Is Impaired By Genetic and Pharmacologic Targeting of LCP1 and PKC Beta

The Impact of the Mutational Landscape upon the Molecular Responses to Interferon-Alfa2 in Calr-Mutated MPN Patients

Comparison of Fluorescence in Situ Hybridization and Flow Cytometry (Flow-FISH) with Monochrome Multiplex Quantitative Polymerase Chain Reaction (MM-qPCR) for Telomere Length Screening in Adult Patients with Suspected Cryptic Dyskeratosis Congenita (DKC)

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Hematopoietic Stem and Progenitor Cell Proliferation and Differentiation Requires the Trithorax Protein Ash2l In Vivo

Androgen Derivatives Improve Blood Counts and Elongate Telomere Length in Patients with Dyskeratosis Congenita

Characterization of Hematopoietic Differentiation Profiles of MPN Patient-Derived Inducible Pluripotent Stem Cells Harboring Homozygous Vs Heterozygous Calreticulin Mutations

Elucidation of Additional Mutations By Next-Generation Sequencing Is of Clinical Significance in Patients with Rare MPNs and MDS/MPN Overlap Syndromes

Dasatinib Exerts Differential Effects on Normal and BCR-ABL Positive Hematopoietic Cells in a Transgenic Mouse Model of Chronic Phase-CML

Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110)

The Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Quality of Life and Productivity: Results from the International MPN Landmark Survey

Classic Cardiovascular Risk Factors and Certain Comorbidities May Contribute to the Risk of Thrombembolic and Bleeding Events in Patients with Classical Myeloproliferative Neoplasms

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only